Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Galapagos could move up to 20% on figotinib decision, says Morgan Stanley » 17:15
10/19/20
10/19
17:15
10/19/20
17:15
GLPG

Galapagos

$130.45 /

+1.465 (+1.14%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GLPG Galapagos
$130.45 /

+1.465 (+1.14%)

GLPG Galapagos
$130.45 /

+1.465 (+1.14%)

10/16/20 UBS
Galapagos price target lowered to EUR 125 from EUR 135 at UBS
10/16/20 RBC Capital
Galapagos price target lowered to $131 from $135 at RBC Capital
10/16/20 Citi
Gilead investors may start questioning Galapagos collaboration, says Citi
10/13/20 Barclays
Galapagos price target lowered to EUR 125 from EUR 140 at Barclays
GLPG Galapagos
$130.45 /

+1.465 (+1.14%)

GLPG Galapagos
$130.45 /

+1.465 (+1.14%)

Friday
Recommendations
Galapagos price target lowered to EUR 125 from EUR 135 at UBS » 12:39
10/16/20
10/16
12:39
10/16/20
12:39
GLPG

Galapagos

$128.00 /

-10.5 (-7.58%)

UBS analyst Laura…

UBS analyst Laura Sutcliffe lowered the firm's price target on Galapagos to EUR 125 from EUR 135 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
GLPG Galapagos
$128.00 /

-10.5 (-7.58%)

GLPG Galapagos
$128.00 /

-10.5 (-7.58%)

10/16/20 RBC Capital
Galapagos price target lowered to $131 from $135 at RBC Capital
10/16/20 Citi
Gilead investors may start questioning Galapagos collaboration, says Citi
10/13/20 Barclays
Galapagos price target lowered to EUR 125 from EUR 140 at Barclays
10/08/20 UBS
Galapagos price target raised to EUR 135 from EUR 130 at UBS
GLPG Galapagos
$128.00 /

-10.5 (-7.58%)

GLPG Galapagos
$128.00 /

-10.5 (-7.58%)

Recommendations
Galapagos price target lowered to $131 from $135 at RBC Capital » 09:24
10/16/20
10/16
09:24
10/16/20
09:24
GLPG

Galapagos

$138.51 /

-5.64 (-3.91%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams lowered the firm's price target on Galapagos to $131 from $135 and keeps a Sector Perform rating on the shares. The analyst cites the company's announcement that its GLPG1972 failed to meet its endpoints in a phase 2 osteoarthritis study, showing no significant difference vs. placebo in any treatment group. Abrahams adds that the price target reduction is modest as he had ascribed only a "limited value to the asset given the challenging indication". However, as "setbacks accumulate", the analyst states that it is important for the upcoming datapoints to "regenerate enthusiasm" for Galapagos' long-term pipeline success.

ShowHide Related Items >><<
GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

10/16/20 Citi
Gilead investors may start questioning Galapagos collaboration, says Citi
10/13/20 Barclays
Galapagos price target lowered to EUR 125 from EUR 140 at Barclays
10/08/20 UBS
Galapagos price target raised to EUR 135 from EUR 130 at UBS
09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

Recommendations
Gilead investors may start questioning Galapagos collaboration, says Citi » 06:44
10/16/20
10/16
06:44
10/16/20
06:44
GILD

Gilead

$62.97 /

-1.1 (-1.72%)

, GLPG

Galapagos

$138.51 /

-5.64 (-3.91%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal believes Gilead Sciences (GILD) investors may start questioning the collaboration with Galapagos (GLPG) after GLPG-1972 failed to show any difference versus placebo in improving knee cartilage thickness at 52-weeks. Gilead has opt-in rights for the U.S. rights to this program and was a key part of last year's new collaboration, Bansal tells investors in a research note. The analyst says that while GLPG-1972 was mentioned last year as a key catalyst for the Galapagos collaboration, he does not have this osteoarthritis asset in his model. Bansal keeps a Buy rating on Gilead with an $80 price target.

ShowHide Related Items >><<
GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

GILD Gilead
$62.97 /

-1.1 (-1.72%)

GILD Gilead
$62.97 /

-1.1 (-1.72%)

09/30/20 Jefferies
Regeneron antibody cocktail results positive for vaccines, says Jefferies
09/24/20 H.C. Wainwright
Durect study designed to support full approval, says H.C. Wainwright
09/20/20 Citi
Immunomedics presents at ESMO, readouts exceeded expectations, says Citi
09/18/20 RBC Capital
Gilead price target raised to $86 from $82 at RBC Capital
GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

10/13/20 Barclays
Galapagos price target lowered to EUR 125 from EUR 140 at Barclays
10/08/20 UBS
Galapagos price target raised to EUR 135 from EUR 130 at UBS
09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

GILD Gilead
$62.97 /

-1.1 (-1.72%)

GILD Gilead
$62.97 /

-1.1 (-1.72%)

GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

GILD Gilead
$62.97 /

-1.1 (-1.72%)

GILD Gilead
$62.97 /

-1.1 (-1.72%)

Thursday
Hot Stocks
Servier, Galapagos announce ROCCELLA trial failed to meet primary objective » 16:22
10/15/20
10/15
16:22
10/15/20
16:22
GLPG

Galapagos

$138.51 /

-5.64 (-3.91%)

Servier and Galapagos…

Servier and Galapagos report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA is a global, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily oral doses of GLPG1972/S201086 in 932 patients with knee osteoarthritis, or OA, over 52 weeks of treatment. The study population was aged between 40 to 76 years, mainly female and with a mean disease duration of 7 years. The primary objective of ROCCELLA was to demonstrate the efficacy of at least one dose of GLPG1972/S201086 compared to placebo after 52 weeks of treatment in reducing cartilage loss of the central medial tibiofemoral compartment of the target knee via quantitative MRI. The trial failed to meet the primary objective. The change from baseline to week 52 in cartilage thickness, in mm was -0.116 for the placebo group and -0.068, -0.097 and -0.085, for the low, medium and high dose, respectively. Statistically significant difference versus placebo was not reached in any of the treated groups.There was no significant difference compared to placebo observed on secondary endpoints, including clinical outcomes.Additional analyses are being conducted to fully evaluate the results, which will be presented at upcoming medical conferences. GLPG1972/S201086 was generally well-tolerated by patients in this Phase 2 trial.

ShowHide Related Items >><<
GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

10/13/20 Barclays
Galapagos price target lowered to EUR 125 from EUR 140 at Barclays
10/08/20 UBS
Galapagos price target raised to EUR 135 from EUR 130 at UBS
09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

GLPG Galapagos
$138.51 /

-5.64 (-3.91%)

Tuesday
Recommendations
Galapagos price target lowered to EUR 125 from EUR 140 at Barclays » 11:58
10/13/20
10/13
11:58
10/13/20
11:58
GLPG

Galapagos

$146.43 /

-0.91 (-0.62%)

Barclays analyst Emily…

Barclays analyst Emily Field lowered the firm's price target on Galapagos to EUR 125 from EUR 140 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
GLPG Galapagos
$146.43 /

-0.91 (-0.62%)

GLPG Galapagos
$146.43 /

-0.91 (-0.62%)

10/08/20 UBS
Galapagos price target raised to EUR 135 from EUR 130 at UBS
09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Jefferies
Galapagos downgraded to Hold from Buy at Jefferies
GLPG Galapagos
$146.43 /

-0.91 (-0.62%)

GLPG Galapagos
$146.43 /

-0.91 (-0.62%)

Over a week ago
Hot Stocks
Gilead and Galapagos present data on filgotinib for UC treatment at UEGW » 09:23
10/12/20
10/12
09:23
10/12/20
09:23
GILD

Gilead

$63.85 /

+0.55 (+0.87%)

, GLPG

Galapagos

$146.51 /

+5.54 (+3.93%)

Gilead Sciences (GILD)…

Gilead Sciences (GILD) and Galapagos (GLPG) presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis, UC. The data from the randomized, double-blind, placebo-controlled, Phase 2b/3 SELECTION trial showed that a significantly igher proportion of patients treated with filgotinib 200 mg, versus placebo, achieved clinical remission at Week 10 and maintained remission through Week 58. In addition, significantly more patients achieved six-month corticosteroid-free remission. The full results were presented at the 2020 United European Gastroenterology Week, UEGW, Virtual Meeting.

ShowHide Related Items >><<
GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

09/30/20 Jefferies
Regeneron antibody cocktail results positive for vaccines, says Jefferies
09/24/20 H.C. Wainwright
Durect study designed to support full approval, says H.C. Wainwright
09/20/20 Citi
Immunomedics presents at ESMO, readouts exceeded expectations, says Citi
09/18/20 RBC Capital
Gilead price target raised to $86 from $82 at RBC Capital
GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

10/08/20 UBS
Galapagos price target raised to EUR 135 from EUR 130 at UBS
09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Jefferies
Galapagos downgraded to Hold from Buy at Jefferies
GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

Hot Stocks
Gilead, Galapagos presents data from Phase 2b/3 trial of filgotinib » 09:20
10/12/20
10/12
09:20
10/12/20
09:20
GILD

Gilead

$63.85 /

+0.55 (+0.87%)

, GLPG

Galapagos

$146.51 /

+5.54 (+3.93%)

Gilead Sciences (GILD)…

Gilead Sciences (GILD) and Galapagos (GLPG) presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis. The data from the randomized, double-blind, placebo-controlled, Phase 2b/3 SELECTION trial showed that a significantly higher proportion of patients treated with filgotinib 200 mg, versus placebo, achieved clinical remission at Week 10 and maintained remission through Week 58. In addition, significantly more patients achieved six-month corticosteroid-free remission. The full results were presented today at the 2020 United European Gastroenterology Week Virtual Meeting. UC is a longer-term condition characterized by inflammation of the mucosal lining of the colon and rectum. An increasingly prevalent disease, UC has a significant impact on the quality of life of more than 2 million people around the world. Despite current treatments, many patients experience fecal urgency, incontinence, recurring bloody diarrhea, and the need to empty their bowels frequently, often accompanied by abdominal pain, poor sleep and fatigue. The SELECTION study included biologic-naive patients, for whom prior conventional therapy had failed, as well as biologic-experienced patients, a high proportion of whom had been non-responders to at least two different lines of prior biologics. In total, 43 percent of patients in the biologic-experienced cohort had failed treatment with both a TNF inhibitor and vedolizumab. The study allowed the enrollment of patients who were taking steroids, and/or immunomodulators, including methotrexate, mercaptopurine or azathioprine, as they would in real-world clinical practice. Overall, 1,348 biologic-naive or biologic-experienced adult patients with moderately to severely active UC were randomized and treated in the SELECTION study. Among biologic-naive patients treated with filgotinib 200 mg, a significantly higher proportion of patients achieved clinical remission at Week 10 compared with placebo. Additionally, a significantly higher proportion of biologic-naive patients treated with filgotinib 200 mg versus placebo achieved Mayo Clinic Score remission, endoscopic remission and histologic remission. A significantly higher proportion of biologic-experienced patients treated with filgotinib 200mg achieved clinical remission at Week 10 compared with placebo. Patients treated with filgotinib who achieved clinical response or remission at Week 10 were re-randomized to their induction dose of filgotinib or placebo in a 2:1 ratio and treated through Week 58. At Week 58, 37.2 percent of patients receiving filgotinib 200 mg achieved clinical remission, compared with 11.2 percent of patients treated with placebo. A significantly higher proportion of those treated with filgotinib 200 mg versus placebo achieved sustained clinical remission, MCS remission, endoscopic remission and histologic remission. Additionally, a significantly higher proportion of patients treated with filgotinib 200 mg achieved six-month corticosteroid-free clinical remission at Week 58 compared with placebo. Overall, the incidence of adverse events, serious AEs and discontinuations due to AEs were similar in the filgotinib and placebo groups in both the induction and maintenance periods of the study. Serious infections, herpes zoster, venous thrombosis, pulmonary embolism and gastrointestinal perforation were infrequent and comparable across treatment groups. The most common adverse events of interest in the induction trials were serious infections, herpes zoster, opportunistic infections and pulmonary embolism. In the maintenance trial, the most common adverse events of interest were serious infections, herpes zoster and venous thrombosis. Two deaths were observed in the filgotinib 200 mg treatment group in the maintenance trial; both adverse events leading to deaths were considered by the study investigators to be unrelated to study drug.

ShowHide Related Items >><<
GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

09/30/20 Jefferies
Regeneron antibody cocktail results positive for vaccines, says Jefferies
09/24/20 H.C. Wainwright
Durect study designed to support full approval, says H.C. Wainwright
09/20/20 Citi
Immunomedics presents at ESMO, readouts exceeded expectations, says Citi
09/18/20 RBC Capital
Gilead price target raised to $86 from $82 at RBC Capital
GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

10/08/20 UBS
Galapagos price target raised to EUR 135 from EUR 130 at UBS
09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Jefferies
Galapagos downgraded to Hold from Buy at Jefferies
GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

GILD Gilead
$63.85 /

+0.55 (+0.87%)

Recommendations
Galapagos price target raised to EUR 135 from EUR 130 at UBS » 12:08
10/08/20
10/08
12:08
10/08/20
12:08
GLPG

Galapagos

$142.01 /

+3.29 (+2.37%)

UBS analyst Laura…

UBS analyst Laura Sutcliffe raised the firm's price target on Galapagos to EUR 135 from EUR 130 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
GLPG Galapagos
$142.01 /

+3.29 (+2.37%)

GLPG Galapagos
$142.01 /

+3.29 (+2.37%)

09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Jefferies
Galapagos downgraded to Hold from Buy at Jefferies
08/24/20 H.C. Wainwright
Galapagos downgraded to Neutral from Buy at H.C. Wainwright
GLPG Galapagos
$142.01 /

+3.29 (+2.37%)

GLPG Galapagos
$142.01 /

+3.29 (+2.37%)

Conference/Events
Galapagos management to meet virtually with Cantor Fitzgerald » 04:55
10/07/20
10/07
04:55
10/07/20
04:55
GLPG

Galapagos

$142.56 /

-4.645 (-3.16%)

Virtual Meeting to be…

Virtual Meeting to be held on October 7 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
GLPG Galapagos
$142.56 /

-4.645 (-3.16%)

GLPG Galapagos
$142.56 /

-4.645 (-3.16%)

09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Jefferies
Galapagos downgraded to Hold from Buy at Jefferies
08/24/20 H.C. Wainwright
Galapagos downgraded to Neutral from Buy at H.C. Wainwright
GLPG Galapagos
$142.56 /

-4.645 (-3.16%)

GLPG Galapagos
$142.56 /

-4.645 (-3.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.